Finance 21 May 2026

Heritage Financial Stock Is Quiet Now, but One Bank Margin Test Could Decide What Comes Next
·····

Heritage Financial Stock Is Quiet Now, but One Bank Margin Test Could Decide What Comes Next

Heritage Financial Corp. shares closed at $27.25 Friday, down 0.33%, lagging bank sector gains as investors weighed the impact of its Olympic Bancorp acquisition. First-quarter net income was $18.9 million, with net interest margin rising to 3.96%. Management expects cost savings after completing systems integration in Q3. A recent SEC filing disclosed a cybersecurity incident involving an internal file-share server.
May 30, 2026
Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
····

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders

Bright Minds Biosciences shares jumped 11.1% to $82.78 after Piper Sandler raised its price target to $220 and reiterated an “Overweight” rating. The company reported C$309.7 million in cash at March 31, up from C$82.9 million in September, and a wider net loss. Lead drug BMB-101 completed Phase 1 and reported Phase 2 data for epilepsy and absence seizures.
May 21, 2026
Bio-Techne Shares Bounce, Investors Eye a Key Risk
····

Bio-Techne Shares Bounce, Investors Eye a Key Risk

Bio-Techne closed Wednesday at $46.70, up 2.7%, marking a three-day rebound but still 35% below its January high. Fiscal third-quarter revenue fell 2% to $311.4 million, missing Wall Street estimates as weak biotech demand and U.S. academic funding cuts weighed on sales. CEO Kim Kelderman described the academic market as “frail” and not on a clear recovery path. Bio-Techne owns 20% of Wilson Wolf and may acquire the rest.
May 21, 2026
Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead
····

Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead

Aterian shares fell 2.5% to $1.15 in premarket trading Thursday after a May 15 filing showed a wider first-quarter loss and raised “substantial doubt” about its ability to continue. The company is seeking stockholder approval to sell major brands for $18 million and issue $7 million in preferred stock, moves that could give investor David E. Lazar control of over 95% of the company.
May 21, 2026
Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
····

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data

Vanda Pharmaceuticals shares fell 0.5% to $6.15 in premarket trading Thursday, trimming part of Wednesday’s 3.2% gain. First-quarter net product sales rose 3% to $51.7 million, but the company posted a $48.6 million net loss and used $50.2 million in operating cash. Vanda raised 2026 revenue guidance to $240–$290 million, expecting Nereus to contribute up to $30 million this year.
May 21, 2026
LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News
····

LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News

Liminatus Pharma agreed to acquire InnocsAI in an all-stock deal, issuing 1.6 billion shares at $0.20 each—over 35 times its current share count. LIMN rose 51% to $0.2844 in premarket trading. The deal would add CAR-T cancer therapy assets, including a candidate authorized for a Phase 1/2a study in South Korea. Liminatus reported $1.91 million in cash and warned of “substantial doubt” about its ability to continue.
May 21, 2026
Aimei Health: Nasdaq Sends AFJK 60-Day Notice
····

Aimei Health: Nasdaq Sends AFJK 60-Day Notice

Aimei Health received a Nasdaq deficiency notice after missing the May 15 deadline for its March-quarter 10-Q filing. Shares traded at $42.18 in pre-market activity ahead of Thursday’s U.S. session. The company has 60 days from the May 19 notice to regain compliance or risk delisting. Aimei is also seeking to complete a merger with United Hydrogen Group, pending regulatory approval.
May 21, 2026
NMFC Stock Moves Higher Ahead of Open as New Mountain Finance Buyback Faces Private Credit Trial
····

NMFC Stock Moves Higher Ahead of Open as New Mountain Finance Buyback Faces Private Credit Trial

New Mountain Finance Corp. closed Wednesday at $8.12, about 26% below its March 31 net asset value of $10.92 per share. The company reported Q1 adjusted net investment income of $32.2 million and declared a 25-cent quarterly distribution. NMFC cut statutory debt-to-equity to 1.12 times and completed a $470 million portfolio sale. Analysts’ average price target stands at $8.54, with most holding a neutral view.
May 21, 2026
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
····

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares closed at $26.95 Wednesday, up 0.3%, with little movement before Thursday’s Nasdaq open. About 90% of participants have been dosed in the registrational Embolden trial for NGN-401, with completion expected in Q2. Neurogene reported $243.2 million in cash as of March 31, enough to fund operations into early 2028. The company’s latest filings were posted May 12, with no new updates since.
May 21, 2026
ARKR Investors Wait on $24 Million Bryant Park Renewal
····

ARKR Investors Wait on $24 Million Bryant Park Renewal

Ark Restaurants shares closed at $6.68, valuing the company at $24.1 million, as investors weighed a 7.6% drop in same-store sales and ongoing lease litigation over its Bryant Park locations. The company posted a net loss of $1.8 million for the quarter ended March 28. Lease uncertainty and weak traffic hit results across all regions. A court hearing on the Bryant Park dispute is set for June 16.
May 21, 2026
XPEL Shares Climb on $110 Million Supply Move, Focus on San Antonio and China Margins
····

XPEL Shares Climb on $110 Million Supply Move, Focus on San Antonio and China Margins

XPEL shares closed up 4.5% at $45.21 Wednesday after the company announced a $110 million investment in manufacturing and supply chain, including a $60.4 million San Antonio property purchase and a new China facility. Financing includes a $44.8 million PNC loan and a Wells Fargo credit amendment. XPEL plans to consolidate operations at the new San Antonio site over the next two years.
May 21, 2026
AREC Stock Jumps as American Resources’ Rare-Earth Pivot Gets a 10-K Test
····

AREC Stock Jumps as American Resources’ Rare-Earth Pivot Gets a 10-K Test

American Resources Corp filed its delayed 2025 annual report on May 20, showing no revenue for the year and a $17.8 million loss from continuing operations, offset by $73.2 million of income from discontinued operations. Shares last traded flat at $2.14 in Thursday premarket after a 10.3% gain Wednesday. The company reported $31.7 million in cash and a swing to $93.2 million in equity. Disclosure controls remain ineffective due to accounting staff shortages.
May 21, 2026
Flexsteel Faces Key Session After 3.5% Stock Gain
····

Flexsteel Faces Key Session After 3.5% Stock Gain

Flexsteel Industries shares rose 3.5% to close at $55.24 Wednesday ahead of a scheduled investor presentation at Sidoti’s Micro-Cap Virtual Investor Conference on Thursday. The company recently bought back 1,279,870 shares for $60.2 million, reducing its share count by about 24%. Net income for the March quarter was $6.4 million, reversing a year-earlier loss. CEO Derek Schmidt and CFO Mike Ressler will address investors.
May 21, 2026
LivePerson Stock Alert: LPSN Rebounds as SoundHound Deal and Insider Filings Put Shares on Watch
····

LivePerson Stock Alert: LPSN Rebounds as SoundHound Deal and Insider Filings Put Shares on Watch

LivePerson shares closed at $2.07 Wednesday, up 3.0% after Tuesday’s drop. SEC filings showed automatic insider sales by CFO John DeNeen Collins and EVP Monica Greenberg to cover taxes on vested stock awards. The stock’s price remains anchored by SoundHound AI’s pending $43 million acquisition, expected to close in the second half of 2026.
May 21, 2026
First Advantage Stock Pops Again — But Investors Are Still Testing the Earnings Story
····

First Advantage Stock Pops Again — But Investors Are Still Testing the Earnings Story

First Advantage shares closed Wednesday up 2.55% at $15.28 after reporting first-quarter revenue of $385.2 million, an 8.6% increase from a year earlier. Net income reached $2.2 million, reversing a $41.2 million loss. The company maintained its 2026 outlook and repurchased $19.5 million in stock during the quarter. Analyst consensus remains Buy, with an average 12-month target of $18.14.
May 21, 2026
Braze Shares Move Ahead of Results as Traders Watch AI Drive and CFO Departure
····

Braze Shares Move Ahead of Results as Traders Watch AI Drive and CFO Departure

Braze Inc shares rose nearly 5% to $22.82 in pre-market trading ahead of its fiscal first-quarter 2027 results, due after the close on May 27. The earnings call will mark CFO Isabelle Winkles’ last before her planned departure on May 29. Braze reaffirmed its guidance in April and has launched new AI products. The company reported $205.2 million in fourth-quarter revenue and ended January with 2,609 customers.
May 21, 2026
AMOD Stock Alert: Alpha Modus’ Android Launch Puts This Tiny Fintech Bet on the Clock
····

AMOD Stock Alert: Alpha Modus’ Android Launch Puts This Tiny Fintech Bet on the Clock

Alpha Modus Holdings’ Alpha Cash app launched on Android, completing rollout across iOS and Android platforms. AMOD shares closed at $0.20 Wednesday, down 5.09%, and traded at $0.21 premarket. The company reported $35,508 in cash and no revenue as of March 31, with a $4 million Q1 net loss. Alpha Cash targets underbanked users but faces competition from larger fintech firms.
May 21, 2026
Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key
····

Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key

Jaguar Health shares rose 9.2% to $3.67 Wednesday after first-quarter revenue jumped to $20.3 million, mainly from a U.S. licensing deal for Mytesi and Canalevia-CA1. Trading volume surged to 593,152 shares. Net loss narrowed to $7.0 million from $10.5 million a year earlier. The company’s crofelemer rare-disease trial advanced with its first pediatric patient entering an extension phase.
May 21, 2026
1 … 23 24 25 26 27 … 212

Stock Market Today

  • Endeavour Group (ASX:EDV) Shares Drop 26% in 3 Months, Valuation at 20% Undervalued
    May 29, 2026, 11:50 PM EDT. Endeavour Group (ASX:EDV) shares have slid about 15% in the past month and 26% over three months, closing at A$2.88. This drop contrasts with analyst estimates placing fair value at A$3.61, signaling a potential 20.2% undervaluation. The company's growth outlook rests heavily on expanding online and omnichannel sales, driven by younger consumers favoring digital retail channels. Sustained revenue growth and improved margins underpin the bullish valuation, but risks remain from cost pressures, competitive pricing, and regulatory changes affecting its high-margin hotel operations. Investors face divergent sentiment, balancing near-term risks against a longer-term recovery in earnings multiples.